Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
暂无分享,去创建一个
Nibedita Bandyopadhyay | Martin Dreyling | Mathias Witzens-Harig | Steven Sun | J. Goldberg | M. Jerkeman | M. Dreyling | J. Bothos | S. Traina | J. Vermeulen | M. Trněný | G. Hess | S. Rule | F. Offner | C. Enny | M. Witzens‐Harig | Shana Traina | Mats Jerkeman | W. Jurczak | Jenna D Goldberg | Seok-Goo Cho | Seok-Goo Cho | I. Bence-Bruckler | C. Rusconi | D. Caballero | Wojciech Jurczak | Rodrigo Santucci Silva | Chiara Rusconi | Marek Trneny | Fritz Offner | Dolores Caballero | Cristina Joao | Georg Hess | Isabelle Bence-Bruckler | John Bothos | Christopher Enny | Sriram Balasubramanian | Jessica Vermeulen | Aleksandra Rizo | Simon Rule | S. Balasubramanian | Steven Sun | C. João | N. Bandyopadhyay | A. Rizo | I. Bence‐Bruckler
[1] Michael L. Wang,et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.
[2] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] S. Ferrero,et al. The current therapeutic scenario for relapsed mantle cell lymphoma , 2013, Current opinion in oncology.
[4] G. Cook,et al. Guidelines for the investigation and management of mantle cell lymphoma , 2012, British journal of haematology.
[5] N. Chiorazzi,et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. , 2012, Blood.
[6] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[7] J. Drach,et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] C. Geest,et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. , 2012, Blood.
[9] L. Gordon,et al. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). , 2013 .
[10] David Cella,et al. The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym) , 2013 .
[11] E. Jaffe,et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. , 2006, Blood.
[12] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[13] Jeffrey A Jones,et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. , 2011, Blood.
[14] M. Ladetto,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] B. Coiffier,et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Martin Dreyling,et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.
[17] Michael L. Wang,et al. Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy , 2014 .
[18] B. Cheson,et al. Development of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma Clinical Research: The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym). , 2005 .
[19] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[20] S. Alkan,et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. , 2013, Leukemia research.
[21] A. Zimmermann,et al. Validation of the Functional Assessment of Cancer Therapy–Lymphoma (FACT-LYM) in Patients with Relapsed/Refractory Mantle Cell Lymphoma , 2008 .
[22] R. Fonseca,et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] E. Hoster,et al. Improvement of overall survival in advanced stage mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Moore,et al. Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma , 2008, Cancer.
[25] M. Roncarolo,et al. Genomic Loss of the Mismatched HLA Locus in Leukemia Is a Major Mechanism of in Vivo Escape from T Cell Immunosurveillance Following Haploidentical HSCT , 2008 .
[26] J. Buggy,et al. Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy , 2012, International reviews of immunology.
[27] W. Khan. Colonel Bruton's Kinase Defined the Molecular Basis of X-Linked Agammaglobulinemia, the First Primary Immunodeficiency , 2012, The Journal of Immunology.
[28] J. Vila-Costas,et al. [Mantle-cell lymphoma]. , 2006, Gastroenterologia y hepatologia.
[29] H. Kluin-Nelemans,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] J. Leonard,et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.